Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6327211 | 0.85 | MEN1 (0.68) | MEN1KMT2AHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL30982746 | 0.85 | MEN1 (0.68) | MEN1KMT2AHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL30982687 | 0.85 | MEN1 (0.68) | MEN1KMT2AHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL30982572 | 0.85 | MEN1 (0.68) | MEN1KMT2AHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL20382958 | 0.85 | HTT (0.71) | MEN1KMT2AHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL8108601 | 0.82 | HTT (0.68) | MEN1KMT2AHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL3358984 | 0.82 | HTT (0.75) | MEN1KMT2AHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL8108280 | 0.81 | HTT (0.67) | MEN1KMT2AHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL8102028 | 0.81 | HTT (0.70) | MEN1KMT2AHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL3289112 | 0.81 | HTT (0.70) | MEN1KMT2AHTTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180201602-A1 | VICINAL PRIMARY DIAMINES ASSOCIATED WITH METAL AND/OR FREE RADICAL CHELATION MOTIFS, AND ACTIVE AGAINST CARBONYL AND OXIDATIVE STRESS, AND USE THEREOF | UNIVERSITE AMIENS PICARDIE JULES VERNE (FR) | 2018-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180201602-A1 | VICINAL PRIMARY DIAMINES ASSOCIATED WITH METAL AND/OR FREE RADICAL CHELATION MOTIFS, AND ACTIVE AGAINST CARBONYL AND OXIDATIVE STRESS, AND USE THEREOF | CAT, GPX1, AOC1 | MEN1 2328/4885KMT2A 1247/4885HTT 2352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.